BlueHaven Therapeutics

Blue Wave Therapeutics is a Munich-based, private biotech company founded in 2020, operating in the rapidly growing radiopharmaceuticals sector. It is developing a novel platform using targeted alginate nanoparticles to deliver radionuclides like Actinium-225 for the precise treatment of solid tumors, starting with glioblastoma. The company is in the preclinical stage, actively seeking a CHF 3.5M+ seed round to advance its lead program and expand its pipeline. Its experienced team has backgrounds in radiopharmaceuticals, oncology development, and significant capital raising.

Proprietary radioactive biopolymer platform using targeted alginate nanoparticles to deliver radionuclide payloads (e.g., Actinium-225) directly to tumor cells.

Blue Wave operates in the highly competitive targeted radiopharmaceutical space, competing against large players like Novartis and Bayer as well as numerous biotechs. Its differentiation hinges on its novel alginate nanoparticle delivery system, which must prove superior in targeting and safety to existing antibody- or small molecule-based radioconjugates.